Aadi bioscience to participate at the jefferies “biotech on the bay” summit

Los angeles, april 18, 2022 (globe newswire) -- aadi bioscience, inc. (“aadi”) (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that founder, chief executive officer and president, neil desai, ph.d., and senior members of aadi's executive team will participate at the jefferies “biotech on the bay” summit, to be held in-person in miami, fl april 26-27, 2022.
AADI Ratings Summary
AADI Quant Ranking